PhRMA Statement on New Strategic Plan from the IP Enforcement Coordinator

WASHINGTON, D.C. (June 19, 2013) – Pharmaceutical Research and Manufacturers of America International Senior Vice President Rod Hunter issued the following statement today on the release of the second Joint Strategic Plan from the Intellectual Property Enforcement Coordinator (IPEC) Victoria Espinel:

New Coalition Seeks to Level the Playing Field for U.S. Businesses Competing in India

06.18.13 | By

A new alliance was launched today to begin educating the public and policymakers about the growing imbalance with the United States’ trading relationship with India and the potential consequences for American job losses if these concerns are not addressed.


06.18.13 | By

Inventor Thomas Edison once said, “If we did all the things we are capable of, we would literally astound ourselves.”

PhRMA Joins with National Minority Quality Forum and Microsoft to Address Diversity in Clinical Trials

WASHINGTON, D.C. (June 18, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that it is partnering with the National Minority Quality Forum (NMQF) and Microsoft to help increase diversity in clinical trials.

PhRMA Statement on Supreme Court Ruling in Patent Settlement Case

WASHINGTON, D.C. (June 17, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued the following statement on the decision issued today by the U.S. Supreme Court in the case of Federal Trade Commission v. Actavis, Inc.:

Women in Government

06.17.13 | By

Last week, we took another step in our fight against chronic disease by extending our successful partnership with the Women in Government Foundation, Inc. (WIG), a national non-profit, non-partisan organization of women state legislators.

Week in Review: Preserving What Works

06.14.13 | By

The first step toward finding solutions in our health care ecosystem is to identify what works, protect what is successful and fix what isn’t. This includes access to medicines, continued research and development and developing programs that get patients the treatments they need.

Castellani Highlights Part D’s Success in Hill Blog

06.14.13 | By

Craving some health policy news on a Friday afternoon? Check out an op-ed that ran in The Hill today from our CEO, John Castellani, on Part D.

Two Key Steps in Elevating Biopharmaceutical Science

06.14.13 | By

Science has been on my mind lately – and for two very good reasons.

PDUFA/FDASIA Implementation Update

06.13.13 | By

As you may know from reading past Catalyst posts, the Prescription Drug User Fee Act (PDUFA) was reauthorized last July when the Food and Drug Safety and Innovation Act (FDASIA) was signed into law.


Subscribe to RSS - Opinion